Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Cushman & Wakefield | CWK | Nov 29, 2024 | 15.30 | -1.16 |
Custom Truck One Source | CTOS | Nov 29, 2024 | 5.98 | -0.33 |
Customers Bancorp | CUBI | Nov 29, 2024 | 56.45 | -0.69 |
Customers Bancorp E Pref | CUBI-E | Nov 29, 2024 | 25.49 | -1.75 |
Customers Bancorp F Pref | CUBI-F | Nov 29, 2024 | 25.19 | -2.47 |
Cutera | CUTR | Nov 29, 2024 | 0.49 | +6.54 |
CVB Financial | CVBF | Nov 29, 2024 | 23.42 | -1.72 |
CVD Equipment | CVV | Nov 29, 2024 | 3.19 | +5.28 |
CVR Energy | CVI | Nov 29, 2024 | 19.35 | +0.42 |
Cvr Partners LP Unit | UAN | Nov 29, 2024 | 81.60 | +7.69 |
CVRx | CVRX | Nov 29, 2024 | 15.32 | +0.07 |
CVS Health | CVS | Nov 29, 2024 | 59.85 | -0.18 |
CXApp A | CXAI | Nov 29, 2024 | 1.67 | +5.03 |
CyberArk Software | CYBR | Nov 29, 2024 | 323.51 | +1.48 |
Cybin | CYBN | Nov 29, 2024 | 10.38 | +1.27 |
Cyclacel Pharmaceuticals | CYCC | Nov 29, 2024 | 0.41 | +17.39 |
Cyclacel Pharmaceuticals Pref | CYCCP | Nov 29, 2024 | 6.75 | 0.00 |
Cyclerion Therapeutics | CYCN | Nov 29, 2024 | 2.20 | +1.85 |
Cyclo Therapeutics | CYTH | Nov 29, 2024 | 0.64 | -10.76 |
Cyngn | CYN | Nov 29, 2024 | 5.68 | -5.49 |
Cytek Biosciences | CTKB | Nov 29, 2024 | 6.53 | +0.46 |
Cytokinetics | CYTK | Nov 29, 2024 | 51.86 | -0.69 |
Cytomed Therapeutics | GDTC | Nov 29, 2024 | 2.35 | +1.73 |
CytomX Therapeutics | CTMX | Nov 29, 2024 | 1.06 | +3.92 |
Cytosorbents | CTSO | Nov 29, 2024 | 0.97 | +6.57 |
D-MARKET Electronic Services & Trading ADR | HEPS | Nov 29, 2024 | 2.97 | +2.77 |
D-Wave Quantum | QBTS | Nov 29, 2024 | 3.02 | +10.22 |
D.R. Horton | DHI | Nov 29, 2024 | 168.78 | -0.38 |
Dada Nexus ADR | DADA | Nov 29, 2024 | 1.46 | +2.10 |
Daily Journal | DJCO | Nov 29, 2024 | 564.51 | -0.18 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.